Cyclo Therapeutics to Present at the Virtual Investor 2022 Top Picks Conference
21 January 2022 - 12:05AM
Business Wire
– Live video webcast presentation on Thursday,
January 27th at 10:00 AM ET
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or
the “Company”), a clinical stage biotechnology company dedicated to
developing life-changing medicines through science and innovation
for patients and families living with diseases, today announced
that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics
will present at the Virtual Investor 2022 Top Picks Conference on
Thursday, January 27, 2022 at 10:00 AM ET.
As part of the virtual event, the Company will provide a brief
presentation, followed by a moderated discussion and an interactive
Q&A session. In addition to the moderated portion of the event,
all investors and interested parties will have the opportunity to
submit questions live during the event. Interested parties may also
pre-submit questions in advance of the live event, which can be
sent via the conference website at virtualinvestorco.com. The
Company will answer as many questions as possible during the
event.
A live video webcast of the virtual event will be availability
on the Events page of the Investors section of the Company’s
website (cyclotherapeutics.com). A webcast replay will be available
two hours following the live presentation and will be accessible
for one year.
About Cyclo Therapeutics
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology
company dedicated to developing life-changing medicines through
science and innovation for patients and families suffering from
disease. The Company’s Trappsol® Cyclo™, an orphan drug designated
product in the United States and Europe, is the subject of four
formal clinical trials for Niemann-Pick Disease Type C, a rare and
fatal genetic disease, (www.ClinicalTrials.gov NCT02939547,
NCT02912793, NCT03893071 and NCT04860960). The Company is planning
an early phase clinical trial using Trappsol® Cyclo™ intravenously
in Alzheimer’s Disease based on encouraging data from an Expanded
Access program for late-onset Alzheimer’s Disease (NCT03624842).
Additional indications for the active ingredient in Trappsol®
Cyclo™ are in development. For additional information, visit the
Company’s website: www.cyclotherapeutics.com.
Safe Harbor Statement
This press release contains “forward-looking statements” about
the company’s current expectations about future results,
performance, prospects and opportunities, including, without
limitation, statements regarding the satisfaction of closing
conditions relating to the offering and the anticipated use of
proceeds from the offering. Statements that are not historical
facts, such as “anticipates,” “believes” and “expects” or similar
expressions, are forward-looking statements. These statements are
subject to a number of risks, uncertainties and other factors that
could cause actual results in future periods to differ materially
from what is expressed in, or implied by, these statements. The
factors which may influence the company’s future performance
include the company’s ability to obtain additional capital to
expand operations as planned, success in achieving regulatory
approval for clinical protocols, enrollment of adequate numbers of
patients in clinical trials, unforeseen difficulties in showing
efficacy of the company’s biopharmaceutical products, success in
attracting additional customers and profitable contracts, and
regulatory risks associated with producing pharmaceutical grade and
food products. These and other risk factors are described from time
to time in the company’s filings with the Securities and Exchange
Commission, including, but not limited to, the company’s reports on
Forms 10-K and 10-Q. Unless required by law, the company assumes no
obligation to update or revise any forward-looking statements as a
result of new information or future events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220120005409/en/
Investor Contact: JTC Team, LLC Jenene Thomas (833)
475-8247 CYTH@jtcir.com
Cyclo Therapeutics (NASDAQ:CYTH)
Historical Stock Chart
From Apr 2024 to May 2024
Cyclo Therapeutics (NASDAQ:CYTH)
Historical Stock Chart
From May 2023 to May 2024